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Abstract It was determined that £avan-3-ols and procyanidins
have an inhibitory e¡ect on angiotensin I converting enzyme
(ACE) activity, and the e¡ect was dependent on the number
of epicatechin units forming the procyanidin. The inhibition
by £avan-3-ols and procyanidins was competitive with the two
substrates assayed: N-hippuryl-L-histidyl-L-leucine (HHL) and
N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine (FAPGG).
Tetramer and hexamer fractions were the more potent inhibi-
tors, showing Ki of 5.6 and 4.7 WM, respectively. As ACE is a
membrane protein, the interaction of £avanols and procyanidins
with the enzyme could be related to the number of hydroxyl
groups on the procyanidins, which determine their capacity to
be adsorbed on the membrane surface.
4 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Several epidemiological studies have shown associations be-
tween the regular consumption of £avonoid-rich foods and a
decreased risk for cardiovascular disease [1^3]. While the in-
verse association between the risk for vascular disease and
dietary £avonoid intake does not prove causality, an increas-
ing amount of experimental data pertaining to certain £avo-
noids does lend support to this association [4].
Flavonoids and other polyphenols are widely distributed in
the human diet, primarily in plant-derived foods and bever-
ages. Procyanidins are a group of polymeric polyphenols com-
posed of the £avan-3-ol units, (3)-epicatechin (epicatechin)
and (+)-catechin (catechin). Procyanidins are present in foods
such as nuts, cranberries, apples, red wine, tea and cocoa or
chocolate [5,6]. Flavan-3-ols and procyanidins are of great
interest in nutrition and medicine because of their potent anti-
oxidant capacity and other protective e¡ects on human
health. In vitro, procyanidins can, among other e¡ects, delay
the rate of low density lipoprotein oxidation [7], reduce the
rate of DNA oxidative damage [8], reduce platelet reactivity
[9,10], and modulate the oxidant-responsive transcription fac-
tor NF-UB [11].
Angiotensin I converting enzyme (ACE) is a glycoprotein
peptidyldipeptide hydrolase, whose main known functions
are to cleave histidyl-leucine from angiotensin I forming
the potent vasoconstrictor angiotensin II, and to degrade
bradykinin to inactive peptides [12]. ACE has two active
sites, N- and C-terminal, with di¡erent a⁄nities for di¡erent
substrates. ACE inhibition is considered to be an important
therapeutic approach in the treatment of high blood pres-
sure, and the intake of certain synthetic ACE inhibitors pro-
vides de¢nitive positive health e¡ects [13]. However, as ACE
inhibitors are pharmacological drugs their use in healthy or
low-risk populations is not advisable. The ¢nding that cer-
tain £avonoid-rich foods can induce reductions in blood
pressure and inhibit ACE activity, both in vivo and in vitro
[14^19], opens up the possibility that consumption of select
£avonoid-rich foods may mimic synthetic ACE inhibitors
and provide health bene¢ts but without adverse side e¡ects.
In this regard, it was observed that after the regular con-
sumption of a diet rich in £avan-3-ols and procyanidins for
14 days, blood pressure was signi¢cantly diminished in aged
people [20].
The aim of the present work was to determine if £avan-3-
ols and procyanidins have an inhibitory e¡ect on ACE activ-
ity, and to characterize such inhibition from a kinetic point of
view. We studied ACE inhibition based on the two commonly
employed methods for determining ACE activity [21,22]. It
was observed that £avan-3-ols and procyanidins isolated
from cocoa compete for enzyme-active sites with synthetic
ACE substrates. The e¡ects of £avan-3-ols and procyanidins
on ACE could contribute to the decreased risk for cardiovas-
cular and other diseases observed in populations that consume
high amounts of foods rich in £avonoids.
2. Materials and methods
2.1. Materials
ACE from rabbit lung (puri¢ed ACE), hippuric acid (HA), hippur-
yl-L-histidyl-L-leucine (HHL), N-[3-(2-furyl)acryloyl]-L-phenylalanyl-
glycylglycine (FAPGG), epicatechin, and catechin were from Sigma
(St. Louis, MO, USA). High-performance liquid chromatography
(HPLC)-grade acetonitrile and acetic acid were from Merck KGaA
(Darmstadt, Germany). Puri¢ed procyanidin fractions (epicatechin
dimers, trimers, tetramers, pentamers, and hexamers) were obtained
from Mars Inc. (Hackettstown, NJ, USA). The purity of the procya-
nidin fractions was 99.0, 94.8, 95.4, 92.0, and 86.2% for dimer, trimer,
tetramer, pentamer, and hexamer fractions, respectively.
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2.2. Inhibition of puri¢ed ACE activity
A mixture consisting of 100 Wl of 6.3 nM puri¢ed ACE and 100 Wl
of £avan-3-ols or procyanidins (0^1500 WM) was preincubated for 30
min at 37‡C. For ACE activity determination, the 200-Wl mixture was
added to 100 Wl of HHL (1.5^12 mM) in 50 mM HCl^Tris, 300 mM
NaCl (pH 8.3) and incubated from 20 to 90 min at 37‡C [21]. The
reaction was stopped by addition of 100 Wl of 12% (w/v) phosphoric
acid. The HA was separated and quanti¢ed by HPLC with UV de-
tection [23]. The system consisted of a Supelcosil LC-18-DB column
(15 cmU4.6 mmU5 Wm) using a mobile phase composed of 5 mM
phosphoric acid:acetonitrile (80:20 v/v), pH 2.5 (£ow rate, 1 ml/min;
retention time, 3.65 min). The UV detection was carried out at 228
nm (Jasco UV 1575, Intelligent UV/VIS Detector, Japan Spectroscop-
ic Co. Ltd.). Commercial HA was used as standard.
For FAPGG hydrolysis determination, a 50-Wl aliquot of the 200 Wl
mixture was added to 280 Wl of FAPGG (50^400 WM) dissolved in
0.1 M potassium phosphate bu¡er, 0.5 M NaCl, 0.1 mM ZnCl2, pH
7.5. After incubating for 10 min at 37‡C, hydrolysis of FAPGG by
ACE was quanti¢ed by recording the decrease of absorbance at 340
nm [22].
2.3. Kinetic calculations
The kinetic parameters were calculated by adjusting curves to the
Michaelis^Menten equation: Vi = (VmaxAUS)/(KMA+S) where Vi =
initial rate; VmaxA = apparent maximum rate; KMA =apparent Mi-
chaelis constant, and S= substrate concentration. KMA and VmaxA
were plotted vs. concentration of inhibitor (I). Ki values were calcu-
lated adjusting the curves to the equation: KMA =KM(1+I/Ki).
The IC50 were calculated by adjusting inhibition curves to the equa-
tion for a two-parameter hyperbolic decay: f= (ViUIC50)/(IC50+I), in
which Vi = initial rate with 1 mM HHL. The Ki values were calculated
from IC50 considering a competitive inhibition with the following
equation: Ki = IC50/(1+(S/KM)). Gibbs free energy (vG) was calcu-
lated as vG=RTln Ki.
2.4. Data analysis
Curves were adjusted using routines available in Sigma Plot 5.0.
Data were analyzed for statistical signi¢cance using ANOVA (Stat-
View 5, Mountain View, CA, USA).
3. Results
3.1. Kinetics of the inhibition of puri¢ed ACE activity by
epicatechin, dimer and hexamer fractions
For the kinetics studies epicatechin, dimer, and hexamer
fractions were used as ACE inhibitors. Inhibition was eval-
uated by means of two di¡erent ACE activity assays, i.e.
HHL and FAPGG hydrolysis. Fig. 1 shows the inhibition
on ACE activity (reduction of Vi) by the hexamer fraction
using the HHL hydrolysis assay (Fig. 1A), and by the dimer
fractions using the FAPGG hydrolysis (Fig. 1B). Similar
curves were obtained when epicatechin or dimer were assayed
as inhibitors of FAPGG hydrolysis, and epicatechin or hex-
amer were assayed inhibiting HHL hydrolysis.
Puri¢ed ACE showed a Michaelis^Menten mechanism us-
ing HHL or FAPGG as substrates. The apparent maximum
rate of substrate hydrolysis (VmaxA) and the apparent Michae-
lis constant (KMA) were determined to characterize the kind of
inhibition exerted by £avan-3-ols and procyanidins. KMA for
both HHL and FAPGG hydrolysis were plotted against epi-
catechin, dimer, or hexamer concentrations (Fig. 1C,D). KMA
values were dependent on the inhibitor and its concentration.
By contrast, the VmaxA were independent of the inhibitor con-
centration (3.0 T 0.3, 3.4 T 0.4, and 3.6 T 0.2 WM min31 for
FAPGG and 0.8T 0.2, 1.2 T 0.3 and 1.5T 0.3 WM min31 for
HHL for epicatechin, dimer, and hexamer, respectively).
These data indicate a competitive enzyme inhibition.
The dissociation constant for the binding of inhibitor to the
free enzyme (Ki) was calculated for the ACE inhibition by
epicatechin, dimer, and hexamer, using both substrates,
HHL and FAPGG. Ki values showed signi¢cant di¡erences
between both substrates for epicatechin (1302 WM for HHL
and 39 WM for FAPGG) and dimer (227 WM for HHL and 35
Fig. 1. Initial velocities for the inhibition of ACE activity by epicatechin, dimer and hexamer vs. substrate concentration (A,B) and KMA vs.
epicatechin, dimer, and hexamer concentrations for HHL (C) or FAPGG (D). Puri¢ed lung ACE was preincubated at 37 ‡C for 30 min in the
absence (control), or the presence of di¡erent amounts of epicatechin, dimer or hexamer, and then incubated from 20 to 90 min in the presence
of di¡erent concentrations of HHL or FAPGG. Values are meanTS.E.M. of at least three independent experiments.
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WM for FAPGG). However, hexamer presented Ki in the same
range with both substrates (4 WM for HHL and 12 WM for
FAPGG). The inhibition of HHL hydrolysis was more clearly
related to the number of monomer units than FAPGG hydro-
lysis.
3.2. Inhibition of puri¢ed ACE activity by epicatechin and
procyanidin fractions
Based on the results obtained above, procyanidins were
tested to investigate whether their inhibitory e¡ect was related
to polymer size. The preincubation of puri¢ed ACE in the
presence of £avan-3-ols or procyanidins inhibited the trans-
formation of HHL into HA in a dose-dependent manner
(Fig. 2). The inhibition was also dependent on the procyani-
din molecular weight. IC50 was 1781T 381, 1593T 443,
267T 24, 126T 11, 12T 1, 25T 3, and 10T 1 WM, for epicate-
chin, catechin, dimer, trimer, tetramer, pentamer, and hexam-
er, respectively.
The dissociation constant for the binding of inhibitor to the
free enzyme (Ki) was calculated taking into account that en-
zyme inhibition was competitive. The Ki were 828, 124, 59,
5.6, 11.6, and 4.7 WM for epicatechin, dimer, trimer, tetramer,
pentamer and hexamer, respectively. These values were on the
same order as those calculated previously by the kinetic assay
for epicatechin (1302 and 828 WM), dimer (227 and 124 WM),
and hexamer (4 and 4.7 WM).
Using the Ki values, changes in Gibbs free energy (vG) were
calculated and IC50 and vG were plotted versus units of
monomers present in procyanidins (Fig. 3). The coe⁄cient
for linear regression (R2) was 0.87 for vG, and the average
energy increase per unit of monomers was 2.6T 0.5 kJ/mol
(P6 0.01).
4. Discussion
We postulate that the observed e¡ect of the consumption
£avonoid-rich foods reducing blood pressure in humans
[20,24] and in rats [25] can be related to the inhibition of
ACE by £avan-3-ols and procyanidins. Flavonoid-containing
plant extracts have been described as possible ACE inhibitors
[14,15,26]. In this study, epicatechin, as well as procyanidins,
inhibited the activity of rabbit lung ACE.
The kinetic analysis of the results suggests that £avan-3-ols
and procyanidins inhibit the enzyme activity by competing
with the substrate for the active sites. The calculated Ki
were di¡erent depending on the type of substrate used
(HHL or FAPGG) for epicatechin and dimer, but were sim-
ilar for the hexamer. It can be suggested that the larger mol-
ecules can inhibit both the C- and the N-active sites to a
similar extent; meanwhile, monomers and dimers seem to in-
hibit preferentially the N-active site.
From thermodynamic considerations, the linear relation-
ship between changes in Gibb’s free energy (vG) and procyan-
idin size, and the calculated binding stabilization enhancement
of about 2.6 kJ/mol/monomer unit, suggest an increase in
hydrogen bond formation between ACE and procyanidin hy-
droxyl groups [27]. The calculated vG values are on the same
order as those estimated for the interaction between hydroxyl
groups and some macromolecules [28,29], but are higher than
those calculated for the interaction between £avonoids and
certain proline-rich proteins [27].
To characterize the relation between the size of procyani-
dins and their ability to inhibit ACE activity, we assayed the
ACE activity using the assay for the hydrolysis of HHL. We
observed that catechin and epicatechin were the weaker inhib-
itors, showing inhibitory e¡ects at concentrations higher than
100 WM. Increasing the number of epicatechin units in the
procyanidin yielded an increasing inhibitory e¡ect. Thus,
three levels of IC50 could be established: IC50 in the mM
range for monomeric £avan-3-ols, in the 100 WM range for
dimer and trimer, and in the 10 WM range for the larger
procyanidins. The relevance of these concentrations should
be interpreted with caution since they were estimated using
non-physiological in vitro conditions (isolated enzyme, syn-
thetic substrates, and high substrate concentration).
With regard to the physiological relevance for the inhibition
of ACE by £avan-3-ols and procyanidins it is important to
note the actual concentrations of these substances in vivo. The
presence of catechin, epicatechin, and dimers has been deter-
mined in human plasma at low micromolar concentrations
Fig. 2. E¡ect of di¡erent concentrations of £avan-3-ols and procya-
nidins on ACE activity. Puri¢ed lung ACE was preincubated at
37‡C for 30 min in the absence (control), or the presence of di¡er-
ent amounts of £avan-3-ols or procyanidins, and then during 60
min in the presence of HHL (5.2 mM). Inhibitors assayed were:
catechin (black triangle up), epicatechin (empty circles), dimer (gray
square), trimer (black triangle down), tetramer (empty diamond),
pentamer (black circle), and hexamer (gray triangle down). Values
are meanTS.E.M. of at least three independent experiments.
Fig. 3. E¡ect of the number of epicatechin units in procyanidins on
IC50 and vG values. Values of IC50 and vG were calculated from
the data shown in this ¢gure, and analyzed mathematically as indi-
cated in Section 2. Inhibitors are epicatechin and procyanidins.
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[30], but there are few reports on tissue concentrations of
monomer and dimer, and no studies addressing the presence
of larger procyanidins in tissues. As ACE is a membrane-
bound enzyme, and £avan-3-ols and procyanidins, especially
the larger molecules, can adsorb to lipid^water interphases
[31], it is feasible that a local enrichment of these compounds
on the membrane surface could lead to an enhanced interac-
tion with the enzyme. This accumulation could take place on
the membranes of vascular endothelial cells, which are
thought to be responsible for regulating blood pressure [32].
Supporting the concept that ACE inhibition could partially
explain the health e¡ects of £avonoids in general, we have
shown that ACE inhibitors can modulate antioxidant defenses
and regulate mitochondrial NO production [33]. Thus, it is
possible to speculate that £avonoids could regulate anti-
oxidant defenses through mechanisms that involve ACE,
underscoring the role of £avan-3-ols and procyanidins in the
modulation of oxidative stress, vascular function and cardio-
vascular disease.
In summary, the results presented here a¡ord a biochemical
base to consider the inhibition of ACE by £avan-3-ols and
procyanidins as a potential mechanism to occur in vivo, ex-
plaining the reduction in blood pressure associated with the
intake of £avanol-rich foods.
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